Loading clinical trials...
Loading clinical trials...
A Phase 1b/2 Study of ARRY-382 in Combination With Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients With Advanced Solid Tumors
Conditions
Interventions
ARRY-382
Pembrolizumab
Locations
30
United States
Ronald Reagan UCLA Medical Center
Los Angeles, California, United States
UCLA Hematology/Oncology
Los Angeles, California, United States
UCLA Hematology/Oncology - Santa Monica
Santa Monica, California, United States
University of Colorado Denver
Aurora, Colorado, United States
University of Colorado Hospital
Aurora, Colorado, United States
Hem-Onc Associates of Treasure Coast
Port Saint Lucie, Florida, United States
Start Date
September 1, 2016
Primary Completion Date
September 17, 2019
Completion Date
October 24, 2019
Last Updated
June 16, 2022
NCT06898450
NCT05719558
NCT07029399
NCT04826341
NCT06819735
NCT06760819
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions